Skip to main content
Fig. 4 | BMC Neurology

Fig. 4

From: Neuroinflammation-associated miR-106a-5p serves as a biomarker for the diagnosis and prognosis of acute cerebral infarction

Fig. 4

MiR-106a-5p reduction alleviates neuroinflammation in microglia treated with OGD. A. MiR-106a-5p inhibitor can reverse the promotion effect of OGD treatment on miR-106a-5p expression in BV-2 cells. B-D. After OGD treatment, the levels of inflammatory cytokines were significantly increased, and miR-106a-5p inhibitor could eliminate the promoting effect of OGD treatment on the release of inflammatory cytokines in BV-2 cells. ***P < 0.001, ###P < 0.001; * compare with untreated, # compare with OGD.

Back to article page

BMC Neurology

ISSN: 1471-2377

Contact us